GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (TSXV:TELO) » Definitions » Total Payout Ratio

Telo Genomics (TSXV:TELO) Total Payout Ratio : 0.00 (As of Dec. 15, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Telo Genomics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Telo Genomics's current Total Payout Ratio is 0.00.


Telo Genomics Total Payout Ratio Historical Data

The historical data trend for Telo Genomics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Total Payout Ratio Chart

Telo Genomics Annual Data
Trend Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 1.96 0.09 1.01 0.24

Telo Genomics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Telo Genomics's Total Payout Ratio

For the Diagnostics & Research subindustry, Telo Genomics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's Total Payout Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Total Payout Ratio falls into.



Telo Genomics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Telo Genomics's Total Payout Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0.65 + 0) / -2.713
=0.24

Telo Genomics's Total Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -0.553
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telo Genomics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.
Executives
Kristan Joseph Weinberg Senior Officer
William John Meekison Director
Hugh Rogers Director

Telo Genomics Headlines

From GuruFocus